Search clinical trials for: Gemcitabine erlotinib capecitabine

Total 5954 results

Konstantin Dragnev
Genentech, Inc.; Ligand Pharmaceuticals

Completed

Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer

Carcinoma, Non-small-cell Lung

United States
Astellas Pharma Inc

Completed

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

United Kingdom, United States, Brazil, Canada, Germany, Korea, Republic of, Poland, Romania, Russian Federation
The First Hospital of Jilin University

Recruiting

A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer

Breast Cancer

China
Anyang Tumor Hospital

Recruiting

Anlotinib for Esophageal Cancer (AFEC)

Esophageal Cancer

China
Guangxi Zhuang Autonomous Region People's Hospital

Recruiting

Anlotinib for Hepatocellular Carcinoma (AFHC)

Liver Neoplasms

China
Shenzhen Second People's Hospital
Dongguan People's Hospital; Zhongshan People's Hospital, Guangdong, China; The... and other collaborators

Recruiting

Nilotinib for First-line Newly Diagnosed CML-CP Patients

Chronic Myeloid Leukemia, Chronic Phase | Nilotinib

China
Shanghai Changzheng Hospital

Recruiting

Anlotinib in Advanced Solid Tumors With FGFR Alteration

Advanced Solid Tumor

China
Andrew J. Wagner, MD, PhD
Massachusetts General Hospital; Novartis; Brigham and Women's Hospital

Active, not recruiting

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Tenosynovial Giant Cell Tumor | Pigmented Villonodular Synovitis | Diffuse-type Giant Cell Tumor

United States
Novartis Pharmaceuticals

No longer available

MAP to Provide Access to Nilotinib, for Patients With HES

Hypereosinophilic Syndrome (HES)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Phase II Study of Anlotinib in STS Patients (ALTN/STS)

Cancer

China
Second Affiliated Hospital, School of Medicine,...

Unknown

Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer

Ovarian Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Unknown

Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC) (ATAHC)

Cancer of Liver
Novartis Pharmaceuticals

Terminated

GSK1120212 Rollover Study

Cancer

France, United States, Netherlands, Canada, Taiwan, Korea, Republic of
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer. (PAAG)

Pancreatic Neoplasms

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage

Gastric Cancer

China
Massachusetts General Hospital

Terminated

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Resectable Pancreatic Cancer | Pancreatic Ductal Carcinoma

United States
University of Texas Southwestern Medical Center
Genentech, Inc.; Celgene

Completed

Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer | Metastatic Cancer

United States
Huazhong University of Science and Technology

Unknown

Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer

Gastric Cancer

China
Daiichi Sankyo, Inc.
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...

Terminated

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Non Squamous, Non-small-cell Lung Cancer

Poland, France, Germany, Italy, Spain, Canada, United States, Argentina, Belgium, Mexico, Australia, Russian Federation, Netherlands, Peru, Brazil, Austria, United Kingdom, Sweden, Czechia, Chile, Denmark, Hungary, Romania
Clovis Oncology, Inc.

Terminated

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy (EGFR)

Non-Small Cell Lung Cancer

Korea, Republic of, United States, Spain, Hong Kong, Taiwan, Germany, Italy
M.D. Anderson Cancer Center
OSI Pharmaceuticals

Terminated

Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin

Skin Cancer

United States
Hoffmann-La Roche

Terminated

A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer

Head and Neck Cancer

Spain
SCRI Development Innovations, LLC
Bayer

Completed

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

Refractory Solid Tumors

United States
Peking University Third Hospital

Not yet recruiting

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer
Korean Breast Cancer Study Group

Unknown

Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer (NeoTG)

Breast Cancer Stage II | Breast Cancer Stage III

Korea, Republic of
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC (Artemis)

Breast Cancer

China
University of Southern California
National Cancer Institute (NCI)

Recruiting

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) (EMPOWER)

Cancer | Metastatic | Breast | Triple Negative | Disseminated Tumor Cell

United States
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline

Completed

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Lung Cancer | Lung Cancer Metastatic | Lung Adenocarcinoma | Lung Cancer Stage IV | Recurrent Lung Adenocarcinoma | Recurrent Lung Cancer

United States
Hoffmann-La Roche

Completed

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Spain, France, United Kingdom, Hong Kong
Centre Francois Baclesse
Hoffmann-La Roche; Groupe Français de Pneumo-Cancérologie

Terminated

A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR (FLARE)

NSCLC Patients With EGFR Activating Mutation

France
Sun Yat-sen University

Unknown

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc (NSCLC EGFR TKI)

Advanced Stage Non Small Cell Lung Cancer

China
NCIC Clinical Trials Group
GlaxoSmithKline

Completed

MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy

Lung Cancer

Canada
Syndax Pharmaceuticals

Terminated

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

Non Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

Familial Adenomatous Polyposis | Attenuated Familial Adenomatous Polyposis

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations

Non-Small Cell Lung Cancer

China, Philippines, Malaysia
Chroma Therapeutics

Terminated

Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
National Taiwan University Hospital

Unknown

Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial (BRILLIANT)

Carcinoma, Non-Small-Cell Lung | Brain Neoplasms

Taiwan
Guangdong Association of Clinical Trials

Terminated

Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation (INNOVATE)

Non-small-cell Lung Cancer

China
Jazz Pharmaceuticals

Not yet recruiting

A Phase 3, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Metastatic HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Metastatic Breast Cancer | Advanced Malignancies | Recurrent Breast Cancer

China
Samsung Medical Center

Completed

A Study of Pazopanib With CAPEOX in AGC Patients

Gastric Cancer

Korea, Republic of
AIO-Studien-gGmbH
iOMEDICO AG

Terminated

Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer (VOXEL)

Colorectal Neoplasms

Germany
Nanjing First Hospital, Nanjing Medical University

Recruiting

A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial (EASOAIPPGL)

Advanced or Metastatic Paraganglioma/ Pheochromocytoma

China
Sun Yat-sen University

Completed

Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

Nasopharyngeal Carcinoma

China
Shanghai General Hospital, Shanghai Jiao Tong University...

Terminated

Anlotinib Treatment in Steroid Depenent/Refractory cGVHD

Chronic Graft-versus-host-disease

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib in Patients With Primary Malignant Bone Tumors

Neoplasm of Bone

China
First Affiliated Hospital of Wenzhou Medical University

Unknown

Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma

Non-Small-Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3

Gastroenteropancreatic Neuroendocrine Tumor G3

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics

Cancer

China
University Health Network, Toronto
Novartis

Terminated

A Study of Nilotinib in Growing Vestibular Schwannomas

Growing Vestibular Schwannomas

Canada

Search clinical trials for: Gemcitabine erlotinib capecitabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations